BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11528549)

  • 1. [Improved results in the treatment of acute myeloid leukemia - Results of study AML-BFM-93 in East Germany with comparisons to the preceding studies AML-I-82 and AML-II-87].
    Steinbach D; Dörffel W; Eggers G; Holfeld E; Kluba U; Krause I; Lauterbach I; Reiss T; Rieske K; Scharfe V; Schumacher R; Weigel H; Weinmann G; Zintl F; Hermann J
    Klin Padiatr; 2001; 213(4):162-8. PubMed ID: 11528549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Improved treatment results in children with AML: Results of study AML-BFM 93].
    Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
    Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group].
    Creutzig U; Ritter J; Heyen P; Berthold F; Henze G; Kabisch H; Lampert F; Niethammer D; Riehm H; Schellong G
    Klin Padiatr; 1992; 204(4):236-45. PubMed ID: 1518259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
    Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
    J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group.
    Vormoor J; Ritter J; Creutzig U; Boos J; Heyen P; Ludwig WD; Harbott J; Löffler H; Schellong G
    Br J Cancer Suppl; 1992 Aug; 18():S63-7. PubMed ID: 1503929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].
    Creutzig U; Zimmermann M; Reinhardt D; Lehrnbecher T
    Klin Padiatr; 2003; 215(3):151-8. PubMed ID: 12778355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Consolidation of therapy of acute myeloid leukemia with the AML-BFM 93 protocol in children in the Czech Republic].
    Starý J; Gajdos P; Blazek B; Ptoszková H; Hrstková H; Kopecná L; Tousovská K; Hak J; Procházková D; Cerná Z; Jabali Y; Timr P; Vávra V; Sedlácek P; Smísek P; Hrusák O; Michalová K
    Cas Lek Cesk; 2004; 143(4):257-63. PubMed ID: 15218726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and effectiveness of high-dose idarubicin during AML induction therapy: results of a pilot study in children.
    Creutzig U; Körholz D; Niemeyer CM; Kabisch H; Graf N; Reiter A; Scheel-Walter H; Bender-Götze C; Behnisch W; Hermann J; Mann G; Ritter J; Zimmermann M
    Klin Padiatr; 2000; 212(4):163-8. PubMed ID: 10994544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating childhood acute myeloid leukaemia with the AML-BFM-83 protocol: experience in a developing country.
    Chan LL; Abdel-Latif ME; Ariffin WA; Ariffin H; Lin HP
    Br J Haematol; 2004 Sep; 126(6):799-805. PubMed ID: 15352983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
    Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
    Creutzig U; Zimmermann M; Ritter J; Reinhardt D; Hermann J; Henze G; Jürgens H; Kabisch H; Reiter A; Riehm H; Gadner H; Schellong G
    Leukemia; 2005 Dec; 19(12):2030-42. PubMed ID: 16304570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognosis, treatment completion, and complications in nonresponders in the study AML-BFM87].
    Kallage V; Müller JE; Zimmermann M; Beck JD; Ritter J; Creutzig U
    Klin Padiatr; 1999; 211(4):250-9. PubMed ID: 10472559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients.
    de Bont ES; Fidler V; Meeuwsen T; Scherpen F; Hählen K; Kamps WA
    Clin Cancer Res; 2002 Sep; 8(9):2856-61. PubMed ID: 12231527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of chemotherapy alone with allogeneic bone marrow transplantation in first full remission in children with acute myeloid leukemia in the AML-BFM-83 and AML-BFM-87 studies--matched pair analysis].
    Creutzig U; Bender-Götze C; Klingebiel T; Ebell W; Friedrich W; Stollmann-Gibbels B; Schmidt H; Suttorp M; Gratwohl A; Heyen P
    Klin Padiatr; 1992; 204(4):246-52. PubMed ID: 1518260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.